RS54820B1 - Postupci za proizvodnju farmaceutski aktivnog agensa - Google Patents

Postupci za proizvodnju farmaceutski aktivnog agensa

Info

Publication number
RS54820B1
RS54820B1 RS20160382A RSP20160382A RS54820B1 RS 54820 B1 RS54820 B1 RS 54820B1 RS 20160382 A RS20160382 A RS 20160382A RS P20160382 A RSP20160382 A RS P20160382A RS 54820 B1 RS54820 B1 RS 54820B1
Authority
RS
Serbia
Prior art keywords
manufacture
processes
active agent
pharmaceutically active
hydrogenating
Prior art date
Application number
RS20160382A
Other languages
English (en)
Inventor
Frans Therkelsen
Michael Harold Rock
Svend Treppendahl
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of RS54820B1 publication Critical patent/RS54820B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Postupak za pripremanje jedinjenja formule IV,koji obuhvata sledeće faze:(a) mešanje (6-fluoro-1H-indol-3-il)acetonitrila, NH3 u vodi i katalizatora na bazi prelaznog metala u alkoholnom rastvaraču; i(b) hidrogenovanje smeše sa H2.Prijava sadrži još 13 patentnih zahteva.
RS20160382A 2009-12-23 2010-12-20 Postupci za proizvodnju farmaceutski aktivnog agensa RS54820B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28953009P 2009-12-23 2009-12-23
PCT/DK2010/050348 WO2011076212A2 (en) 2009-12-23 2010-12-20 Processes for the manufacture of a pharmaceutically active agent
EP10803222.8A EP2516394B1 (en) 2009-12-23 2010-12-20 Processes for the manufacture of a pharmaceutically active agent

Publications (1)

Publication Number Publication Date
RS54820B1 true RS54820B1 (sr) 2016-10-31

Family

ID=43567689

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160382A RS54820B1 (sr) 2009-12-23 2010-12-20 Postupci za proizvodnju farmaceutski aktivnog agensa

Country Status (37)

Country Link
US (3) US8461353B2 (sr)
EP (1) EP2516394B1 (sr)
JP (2) JP5864435B2 (sr)
KR (2) KR101796330B1 (sr)
CN (2) CN103694161B (sr)
AR (1) AR079580A1 (sr)
AU (1) AU2010335659B2 (sr)
BR (1) BR112012015749A2 (sr)
CA (1) CA2785440C (sr)
CL (1) CL2012001725A1 (sr)
CR (1) CR20120316A (sr)
CY (1) CY1118032T1 (sr)
DK (1) DK2516394T3 (sr)
DO (1) DOP2012000170A (sr)
EA (1) EA021440B1 (sr)
ES (1) ES2575666T3 (sr)
GE (1) GEP20146078B (sr)
HK (2) HK1174921A1 (sr)
HR (1) HRP20160518T1 (sr)
HU (1) HUE028806T2 (sr)
IL (2) IL220329A (sr)
MA (1) MA33945B1 (sr)
ME (1) ME02401B (sr)
MX (1) MX2012007078A (sr)
MY (1) MY159251A (sr)
NZ (2) NZ600639A (sr)
PL (1) PL2516394T3 (sr)
PT (1) PT2516394E (sr)
RS (1) RS54820B1 (sr)
SG (1) SG181910A1 (sr)
SI (1) SI2516394T1 (sr)
SM (1) SMT201600166B (sr)
TN (1) TN2012000279A1 (sr)
TW (1) TW201139370A (sr)
UA (1) UA111584C2 (sr)
WO (1) WO2011076212A2 (sr)
ZA (1) ZA201305936B (sr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
JO3639B1 (ar) * 2014-07-04 2020-08-27 H Lundbeck As صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
CN104130174A (zh) * 2014-07-30 2014-11-05 天津市斯芬克司药物研发有限公司 一种吲唑衍生物及其制备方法
CN105175307A (zh) * 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途
CN104529865B (zh) * 2014-12-12 2017-02-01 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
US20160168089A1 (en) 2014-12-12 2016-06-16 H. Lundbeck A/S Process for the manufacture of idalopirdine
MA41148A (fr) * 2014-12-12 2017-10-17 H Lundbeck As Procédé de fabrication d'idalopirdine
WO2017067670A1 (en) 2015-10-23 2017-04-27 Pharmathen S.A. A novel process for the preparation of tryptamines and derivatives thereof
WO2017174691A1 (en) 2016-04-08 2017-10-12 H. Lundbeck A/S A process for the manufacture of idalopirdine via hydrogenation of an imine
EP3333154A1 (en) 2016-12-07 2018-06-13 Sandoz Ag Crystalline form of a selective 5-ht6 receptor antagonist

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3042685A (en) 1962-07-03 Process of making g-fluoro tryptamine
GB846675A (en) * 1958-04-18 1960-08-31 Lab Francais Chimiotherapie Process for the production of a tryptamine derivative
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
DE69413560T2 (de) 1993-12-28 1999-04-22 Rhone Poulenc Fibres Verfahren zur herstellung eines katalysators für die hydrierung von nitrilen in aminen und verwendung dieses katalysators in der hydrierung
CN1075806C (zh) 1993-12-28 2001-12-05 罗纳布朗克化学公司 在掺杂阮内镍型催化剂存在下腈催化加氢生成胺的方法
US5869653A (en) 1997-10-30 1999-02-09 Air Products And Chemicals, Inc. Hydrogenation of nitriles to produce amines
JP2001508197A (ja) 1997-10-31 2001-06-19 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 構成信号にノイズを加算してｌｐｃ原理により符号化された音声のオーディオ再生のための方法及び装置
US6156694A (en) 1998-11-05 2000-12-05 E. I. Dupont De Nemours & Company Raney cobalt catalyst and a process for hydrogenating organic compounds using said catalyst
EP1379239B1 (en) * 2001-03-29 2007-09-12 Eli Lilly And Company N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor
US7084154B2 (en) * 2003-02-11 2006-08-01 Pharmacopeia Drug Disclovery, Inc. 2-(aminomethyl) arylamide analgesics
FR2866335B1 (fr) 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
JP2006169113A (ja) * 2004-12-10 2006-06-29 Dainippon Sumitomo Pharma Co Ltd インドール類の合成方法および合成中間体
RU2008128823A (ru) 2005-12-15 2010-01-20 Экселиксис, Инк. (Us) Производные азепиноиндола в качестве фармацевтических средств
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
JO2704B1 (en) * 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010036362A1 (en) * 2008-09-26 2010-04-01 Wyeth 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
CN101531624A (zh) 2009-04-08 2009-09-16 大连凯飞精细化工有限公司 6-氟吲哚-3-乙腈的合成方法
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent

Also Published As

Publication number Publication date
TN2012000279A1 (en) 2013-12-12
US9382205B2 (en) 2016-07-05
KR101873182B1 (ko) 2018-06-29
CA2785440A1 (en) 2011-06-30
GEP20146078B (en) 2014-04-10
HK1174921A1 (en) 2013-06-21
KR20170125417A (ko) 2017-11-14
KR20120112480A (ko) 2012-10-11
US8901318B2 (en) 2014-12-02
HUE028806T2 (en) 2017-01-30
UA111584C2 (uk) 2016-05-25
US20110152539A1 (en) 2011-06-23
CY1118032T1 (el) 2017-05-17
CL2012001725A1 (es) 2012-11-30
CN102656146B (zh) 2014-12-17
CN103694161B (zh) 2015-09-09
AU2010335659A1 (en) 2012-07-05
WO2011076212A3 (en) 2011-08-11
EP2516394A2 (en) 2012-10-31
HK1196352A1 (en) 2014-12-12
IL231141A0 (en) 2014-03-31
NZ625798A (en) 2014-10-31
JP6195605B2 (ja) 2017-09-13
KR101796330B1 (ko) 2017-11-09
TW201139370A (en) 2011-11-16
ME02401B (me) 2016-09-20
CN103694161A (zh) 2014-04-02
JP2013515683A (ja) 2013-05-09
MY159251A (en) 2016-12-30
EA021440B1 (ru) 2015-06-30
EA201290552A1 (ru) 2012-12-28
US8461353B2 (en) 2013-06-11
HRP20160518T1 (hr) 2016-06-03
WO2011076212A2 (en) 2011-06-30
IL220329A0 (en) 2012-08-30
PL2516394T3 (pl) 2016-09-30
IL231141A (en) 2016-03-31
AR079580A1 (es) 2012-02-01
DOP2012000170A (es) 2012-08-31
ES2575666T3 (es) 2016-06-30
JP5864435B2 (ja) 2016-02-17
CR20120316A (es) 2012-08-16
MX2012007078A (es) 2012-07-20
EP2516394B1 (en) 2016-03-16
SMT201600166B (it) 2016-07-01
ZA201305936B (en) 2015-09-30
US20130245281A1 (en) 2013-09-19
NZ600639A (en) 2014-07-25
MA33945B1 (fr) 2013-01-02
SI2516394T1 (sl) 2016-07-29
AU2010335659B2 (en) 2015-05-21
SG181910A1 (en) 2012-08-30
DK2516394T3 (en) 2016-06-13
CA2785440C (en) 2018-05-01
IL220329A (en) 2016-03-31
US20150080584A1 (en) 2015-03-19
BR112012015749A2 (pt) 2015-09-15
CN102656146A (zh) 2012-09-05
PT2516394E (pt) 2016-06-07
JP2016117734A (ja) 2016-06-30

Similar Documents

Publication Publication Date Title
RS54820B1 (sr) Postupci za proizvodnju farmaceutski aktivnog agensa
BRPI0612957B8 (pt) composto, processos de preparação de compostos, composição farmacêutica e uso de um composto
TW200942524A (en) Novel aminomethyl benzene derivatives
CL2011000166A1 (es) Metodo para preparar tetrahidrobiopterina hidrolizando diacetilbiopterina a biopterina en presencia de una base en una mezcla bifasica de agua y solvente organico no miscible en agua e hidrogenando biopterina a tetrahidrobiopterina en presencia de un catalizador, ambas etapas a un ph de al menos 10 (divisional de la solicitud de patente de invencion no. 7-2009).
WO2010116256A3 (en) Thinning agent
ATE494292T1 (de) Eine pentakis(dimethylamino)disilanvorstufe enthaltende verbindung, und verfahren zu deren herstellung
UA97806C2 (ru) Бензиламины, способ их получения и их применения в качестве противовоспалительных средств
CL2012000374A1 (es) Metodo para la preparacion de una composicion saborizante activa que comprende una primera reaccion entre un compuesto amino y un carbonilo, resultando una primera mezcla de intermediarios, una segunda reaccion con un segundo compuesto amino solo o en combinacion con un compuesto carbinilo, resultando una segunda mezcla de intermediarios, reacciones serparadas adicionales con compuestos de otras clases quimicas, ultima reaccion que comprende una mezcla de todas las mezclas de intermediarios anteriores.
WO2009138847A3 (en) An improved process for the preparation of cefozopran
EP3722277A3 (en) 3'end caps for rna-interferring agents for use in rna
BRPI0912163A2 (pt) Composto químico, processo para a produção de um composto, compsição química, e, uso de um composto químico.
WO2008043366A3 (en) Three-domain compounds for transmembrane delivery
MX365072B (es) Procedimiento de preparacion de bifenilos sustituidos mediante activacion c-h.
WO2011016052A3 (en) Process for preparing pregabalin
ATE517900T1 (de) Heptarylen-und octarylentetracarbonsäurediimide und deren herstellung
WO2008024277A3 (en) Kw-3902 conjugates that do not cross the blood-brain barrier
GEP20156422B (en) Method for enzymatic synthesis of (7s)-1-(3,4-dimethoxybicyclo [4.2.0]octa-1,3,5-triene-7-yl)n-methyl methanamine and application therein ivabradine synthesis
EA200901498A1 (ru) Водная фармацевтическая композиция
MX2013004092A (es) Proceso de preparacion de clorhidrato de (6r) -tetrahidrobiopterina.
WO2009101458A3 (en) New polymorph and amorphous forms of desvenlafaxine fumarate
MA32698B1 (fr) Procede de preparation du 1,6:2,3-dianhydro-beta-d-mannopyranose
WO2011031764A3 (en) Compounds and related methods of use
WO2007096261A3 (en) Process for the preparation of dioxane derivatives
WO2010023688A3 (en) An improved process for the preparation of eprosartan
EA201400171A1 (ru) Способ ферментативного синтеза (7s)-3,4-диметоксибицикло[4.2.0]окта-1,3,5-триен-7-карбоновой кислоты и применение в синтезе ивабрадина и его солей